Article

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants

2022-02-17

Abstract excerpt

The ongoing evolution of SARS-CoV-2 has resulted in the emergence of Omicron, which displays striking immune escape potential. Many of its mutations localize to the spike protein ACE2 receptor-binding domain, annulling the neutralizing activity of most therapeutic monoclonal antibodies. Here we describe a receptor-blocking human monoclonal antibody, 87G7, that retains ultrapotent neutralization against SARS-CoV-2...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0f1047aa-c0f1-5729-a991-4c95e9228209
DOI: 10.1101/2022.02.17.480751

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsDOI 10.1101/2022.02.17.480751Read

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shiftSemantic proximity Read

Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsSemantic proximity Read

Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsSemantic proximity Read

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibodySemantic proximity Read

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsSemantic proximity Read

Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike proteinSemantic proximity Read

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsSemantic proximity Read

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.Semantic proximity Read

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Semantic proximity Read

Structural insight into antibody evasion of SARS-CoV-2 omicron variantSemantic proximity Read

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variantsSemantic proximity Read

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read